Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001472375-24-000090
Filing Date
2024-11-04
Accepted
2024-11-04 11:44:30
Documents
45
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT FOR THE PERIOD ENDED SEPTEMBER 30, 2024 ixform10q.htm   iXBRL 10-Q 450543
2 CERTIFICATION exhibit31-1.htm EX-31.1 11189
3 CERTIFICATION exhibit31-2.htm EX-31.2 11312
4 CERTIFICATION exhibit32-1.htm EX-32.1 4420
5 CERTIFICATION exhibit32-2.htm EX-32.1 4462
6 regenerexlogo.gif GRAPHIC 5716
  Complete submission text file 0001472375-24-000090.txt   2387137

Data Files

Seq Description Document Type Size
7 SCHEMA DOCUMENT rgpx-20240930.xsd EX-101.SCH 21589
8 CALCULATION LINKBASE DOCUMENT rgpx-20240930_cal.xml EX-101.CAL 34296
9 DEFINITION LINKBASE DOCUMENT rgpx-20240930_def.xml EX-101.DEF 86407
10 LABELS LINKBASE DOCUMENT rgpx-20240930_lab.xml EX-101.LAB 173200
11 PRESENTATION LINKBASE DOCUMENT rgpx-20240930_pre.xml EX-101.PRE 144164
47 EXTRACTED XBRL INSTANCE DOCUMENT ixform10q_htm.xml XML 181874
Mailing Address 5348 VEGAS DRIVE, SUITE 177 LAS VEGAS NV 89108
Business Address 5348 VEGAS DRIVE, SUITE 177 LAS VEGAS NV 89108 305-927-5191
REGENEREX PHARMA, INC. (Filer) CIK: 0001357878 (see all company filings)

EIN.: 980479983 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 000-53230 | Film No.: 241421660
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)